CRS Clinical Research Services Mannheim GmbH is looking for participants (m/f/d) for an important COVID-19 vaccination study and will provide an expense allowance
Mannheim – There are approximately 30,000 known diseases worldwide. However, much of it is not yet satisfactorily treated. And that’s exactly why clinical trials are needed to drive the development of new drugs and treatment options.
Currently leading the CRS Clinical Research Services Mannheim GmbH an important COVID-19 vaccination study (omicron variant) for which women and men are currently being sought.
If you meet the requirements, you can make a valuable contribution as a test person. Be a #medicine advancer!
© CRS Clinical Research Services
Die CRS Clinical Research Services Mannheim GmbH currently leading an important COVID-19 vaccination study (omicron variant) for the current Women and men aged 18-59 years be searched.
This study evaluates the safety and efficacy of an investigational vaccine booster once morest the omicron variant of the original SARS-CoV-2 virus.
Women and men who have been vaccinated at least two or at most three times with an approved mRNA vaccine and who have had a corona infection from January 2022 can take part.
And for that we need you – as a volunteer test person!
Requirements for the current study (study no. 100/21):
- women and men
- Age 18-59 years
- vaccinated at least two, max. three times with an approved mRNA-COVID-19 vaccine and then (from January 2022) contracted COVID-19 (vaccination certificate and PCR proof required)
- no acute illnesses
- stable chronic diseases are allowed
- No participation in the study 30 days beforehand
You will receive an expense allowance (depending on the group allocation) of 250 to 350 euros plus reimbursement of travel expenses for full participation in the study.
© CRS Clinical Research Services
Scope of study:
- information event
- preliminary examination
- 3-5 traveling visitors
- final examination
From the preliminary examination to the final examination, the study takes regarding 3-12 months (depending on the group assignment).
1st information event
A non-binding registration is followed by an information event with one of the doctors, in which you will be informed regarding the course of the study. Here you can also clarify all open questions. You then have sufficient time to decide whether to participate.
2. Education and preliminary investigation
This is followed by a medical explanation, i.e. a private conversation with a doctor, during which you have the opportunity to ask questions once more. If you decide to take part in the study, you give your written consent to participate. You can withdraw your consent at any time without giving reasons. There are no disadvantages for you as a result.
After that, a thorough preliminary examination takes place – a comprehensive health check, in which it is checked whether you are suitable as a test subject for the study. For this purpose, height and weight are recorded, blood and urine are examined and your medical history is examined more closely.
3. Main inspection
If the preliminary examination has shown that you are suitable for the study, you will be given the study drug a few days later. During the study itself, you will be individually looked following by experienced doctors and nursing staff.
4. Final examination
At the end of the study, you will receive a detailed final examination to ensure that you leave the study as healthy as you started it.
Good to know:
1. As a test subject, you make an important contribution to the development of new medicines and ensure that patients can be better helped in the future.
2. You will receive an expense allowance and often your travel expenses will also be reimbursed.
3. You may receive far more medical benefits than are normally provided as part of standard medical care.
